

PATENT

Docket No. JCLA21512-R

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of : ULRICH BOGDAHN et al.
Application No. : 10/597,813
Filed : April 13,2007
For : INHIBITORS OF TGF-R SIGNALING FOR TREATMENT OF CNS
DISORDERS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Enclosed herewith are a European Search Report and a Form PTO-1449 listing (5) reference that are also enclosed. Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application. This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(c), i.e. after a first Office Action is sent but before a final Office Action or a Notice of Allowance is sent.

The Commissioner is authorized to charge necessary fee in the amount of \$ 180 for covering the fee set forth in 37 CFR §1.17(p) or any other fees required in connection with the filing of this paper to our Deposit Account No. 50-0710 (Order No. JCLA21512-R).

The submission of the references should not be interpreted as admitting them as prior art.

Respectfully submitted,

Dated: March 1, 2010

By: /JIAWEI HUANG/

Jiawei Huang
Registration No. 43,330

Correspondence Address:

J.C. Patents
4 Venture, Suite 250
Irvine, California 92618
Tel: (949) 660-0761